Stocks
Novo's series of unfortunate events
Eli wins this round, while Novo continues to flounder.
Eli wins this round, while Novo continues to flounder.
Shares sank on the news.
The two pharma companies are duking it out for the future of weight-loss drugs.
Both pharma giants are working to create new obesity pills.
Martin Shkreli is shorting a pharmaceutical company, and people are listening to him for some reason.
The Danish pharma giant is desperate to close the gap with Eli Lilly.
Weight-loss drugs were a hot ticket last quarter, so why are all the companies that sell them down?
Stay up to date on the latest market news with daily analysis of the investing landscape, served up Brew-style.
By subscribing, you accept our Terms & Privacy Policy.